Pharmacokinetics of Intracellular TFV-DP and FTC-TP in HIV-infected Adolescents
Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in Children
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Awewura Kwara, MD
- Phone Number: 352-273-9501
- Email: awewura.kwara@medicine.ufl.edu
Study Contact Backup
- Name: Oluwayemisi Ojewale, MBChB, MPH
- Phone Number: 3522739446
- Email: oawoyemi@ufl.edu
Study Locations
-
-
-
Kumasi, Ghana
- Kwame Nkrumah University of Science and Technology
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- HIV-infected adolescents aged 10 to 19 years old who are stable on antiretroviral regimen containing TDF/FTC (300/200 mg daily) for at least 8 weeks.
Exclusion Criteria:
- Unable to obtain informed signed consent from parent(s) or legal guardian.
- Pregnant or breast feeding.
- Require therapy for other opportunistic infections other than tuberculosis (TB).
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
HIV only
Adolescents aged 10-19 years with HIV infection
|
Effect of antituberculosis treatment, age and genetic factors on intracellular TFV-DP and FTC-TP concentrations
|
|
HIV/TB
Adolescents aged 10-19 years with HIV and TB coinfection
|
Effect of antituberculosis treatment, age and genetic factors on intracellular TFV-DP and FTC-TP concentrations
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Average concentration (Cav) of intracellular TFV-DP and FTC-TP in Ghanaian HIV-infected adolescents.
Time Frame: After at least 8 weeks of HIV therapy.
|
Mean and median Cav of intracellular TFV-DP and FTC-TP in Ghanaian HIV-infected adolescents.
|
After at least 8 weeks of HIV therapy.
|
|
Area under the time-concentration curve 0-24 hours (AUC0-24h) of intracellular TFV-DP and FTC-TP in Ghanaian HIV-infected adolescents.
Time Frame: After at least 8 weeks of HIV therapy.
|
Mean and median AUC0-24h of intracellular TFV-DP and FTC-TP in Ghanaian HIV-infected adolescents.
|
After at least 8 weeks of HIV therapy.
|
|
Cav of TFV-DP and FTC-TP PK in HIV-infected adolescents with and without TB coinfection.
Time Frame: After at least 8 weeks of HIV therapy.
|
Geometric mean intracellular TFV-DP and FTC-TP Cav in adolescents with TB/HIV coinfection compared to those only HIV infection.
|
After at least 8 weeks of HIV therapy.
|
|
AUC0-24h of TFV-DP and FTC-TP PK in HIV-infected adolescents with and without TB coinfection.
Time Frame: After at least 8 weeks of HIV therapy.
|
Geometric mean of intracellular TFV-DP and FTC-TP AUC0-24h in adolescents with TB/HIV coinfection compared to those with only HIV infection.
|
After at least 8 weeks of HIV therapy.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Effect of age on TFV-DP and FTC-TP Cav.
Time Frame: After at least 8 weeks of HIV therapy.
|
Geometric mean of intracellular TFV-DP and FTC-TP Cav in adolescents aged 10 - 14 years old compared to that in adolescents aged 15 - 19 years old.
|
After at least 8 weeks of HIV therapy.
|
|
Effect of age on TFV-DP and FTC-TP AUC0-24h .
Time Frame: After at least 8 weeks of HIV therapy.
|
Geometric mean of intracellular TFV-DP and FTC-TP AUC0-24h in adolescents aged 10 - 14 years old compared to that in adolescents aged 15 - 19 years old.
|
After at least 8 weeks of HIV therapy.
|
|
Intracellular TFV-DP and FTC-TP Cav in adolescents compared to that in historical adult controls.
Time Frame: After at least 8 weeks of HIV therapy.
|
Geometric mean of intracellular TFV-DP and FTC-TP Cav in Ghanaian HIV-infected adolescent compared to published values in adults treated with similar dosage.
|
After at least 8 weeks of HIV therapy.
|
|
Intracellular TFV-DP and FTC-TP AUC0-24h in adolescents compared to that in historical adult controls.
Time Frame: After at least 8 weeks of HIV therapy.
|
Geometric mean of intracellular TFV-DP and FTC-TP AUC0-24h in Ghanaian HIV-infected adolescent compared to published values in adults treated with similar dosage.
|
After at least 8 weeks of HIV therapy.
|
|
Relationship between Adenosine triphosphate (ATP)-binding cassette subfamily C, member 2 (ABCC2), member 4 (ABCC4) and member 10 (ABCC10) SNPs and TFV-DP and FTC-TP AUC0-24h.
Time Frame: After at least 8 weeks of HIV therapy.
|
Relationship between ABCC2, ABCC4 and ABCC10 SNPs and intracellular TFV-DP and FTC-TP AUC0-24h.
|
After at least 8 weeks of HIV therapy.
|
|
Prevalence and covariates of intracellular TFV-DP Cav < 95 fmol/106 cells in adolescents.
Time Frame: After at least 8 weeks of HIV therapy.
|
Proportion of Ghanaian adolescents and factors associated with intracellular TFV-DP average concentration < 95 fmol/106 cells.
|
After at least 8 weeks of HIV therapy.
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Awewura Kwara, MD, University of Florida
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Actinomycetales Infections
- Mycobacterium Infections
- Slow Virus Diseases
- Urogenital Diseases
- Genital Diseases
- HIV Infections
- Tuberculosis
- Acquired Immunodeficiency Syndrome
- Coinfection
Other Study ID Numbers
Other Study ID Numbers
- IRB201801820 - PKAdol
- 2R01HD071779 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.